In 2013, Johnson & Johnson introduced the diabetes drug Invokana to the market. Invokana was the first member of a new class of diabetes drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors – a drug designed to work by inhibiting some kidney functions to increase the amount of sugar excreted in urine.
A little more than two years after Invokana’s introduction to the market, the U.S. Food and Drug Administration (“FDA”) issued a warning about serious risks associated with Invokana and other similar SGLT2 inhibitors. The FDA, in its May 2015 report, highlighted more than 20 adverse event reports linked to SGLT2 inhibitors, each of which resulted in hospitalization or emergency room treatment.
Problems associated with Invokana include kidney failure, kidney impairment, kidney stones, urinary tract infections, and abnormal weight loss. The FDA has cautioned patients to be aware of the potential link between Invokana and diabetic ketoacidosis – a condition of high levels of acid accumulating in the blood. Difficulty breathing, nausea or vomiting, abdominal pain, confusion, fatigue and sleeplessness are all symptoms of ketoacidosis.
Wexler Wallace is currently representing individuals who are or have taken Invokana and experienced complications or side effects from taking the drug. If you or a loved one has suffered from diabetic ketoacidosis or experienced any adverse symptoms from taking Invokana, please contact us to speak to an attorney about your potential claim.